City

Houston (2)

Bethesda (1)

San Francisco (1)

Overall Status

Terminated (2)

Completed (1)

No longer available (1)

Phase

phase 2 (3)

Sponsor

Baylor College of Medicine (2)

Christopher Dvorak (1)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1)

Collaborator

The Methodist Hospital Research Institute (2)

Center for Cell and Gene Therapy, Baylor College of Medicine (1)

Study Documents

Intervention Type

drug (3)

biological (1)

procedure (1)

Funder Type

Other (3)

NIH (1)

Study Type

Interventional (3)

Expanded Access (1)

hemoglobinopathy

Showing 1 - 4 of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia Trial in San Francisco (CD34+ enriched, T Cell

No longer available

Acute Lymphoblastic Leukemia
+11 more

CD34+ enriched, T Cell Depleted donor stem cell product

San Francisco, California

University of California, San Francisco

May 25, 2021

Sickle Cell Anemia, Hemoglobinopathy, Thalassemia Trial in Houston (FLUDARABINE, CAMPATH-IH, Total Body Irradiation)

Terminated

Sickle Cell Anemia
+2 more

FLUDARABINE
+4 more

Houston, Texas
+1 more

Jan 15, 2020

Sickle Cell Anemia, Hemoglobinopathy, Thalassemia Trial in Houston (Campath -1H, Dilantin, Busulfan)

Terminated

Sickle Cell Anemia
+2 more

Campath -1H
+3 more

Houston, Texas
+1 more

Jan 15, 2020

Beta Thalassemia, Hemoglobinopathy Trial run by the NIDDK (Hydroxyurea)

Completed

Beta Thalassemia
Hemoglobinopathy

Hydroxyurea

Bethesda, Maryland

National Institute of Diabetes and Digestive and Kidney Diseases

Mar 3, 2008